CellaVision AB (C26) Stock Forecast & Price Target
C26 Analyst Ratings
There are no analyst ratings in the last 3 months.
C26 Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christian Lee | Pareto | EUR 13.64 | hold | -22.59%Downside | Downgraded | 07/13/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christian Lee | 07/13/26 | EUR 13.64 | hold | -22.59%Downside | Downgraded | Pareto |
Best Analysts Covering CellaVision AB
Copying OpenAI Medical - Devices's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +1.24% per trade.
Copying OpenAI Medical - Devices's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +2.66% per trade.
Copying OpenAI Medical - Devices's trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +2.66% per trade.
C26 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 1 | 1 | 1 | 0 |
In the current month, C26 has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. C26 average Analyst price target in the past 3 months is ―.
C26 Financial Forecast
C26 Earnings Forecast
Next quarter’s earnings estimate for C26 is EUR 0.19 with a range of EUR 0.17 to EUR 0.20. The previous quarter’s EPS was EUR 0.16. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
C26 Sales Forecast
Next quarter’s sales forecast for C26 is EUR 19.91M with a range of EUR 19.16M to EUR 20.89M. The previous quarter’s sales results were EUR 18.12M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.